Skip to main content
Clinical Trials/IRCT2017100136491N1
IRCT2017100136491N1
Recruiting
Phase 2

Evaluation of clinical and histopathological efficacy of carboplatin and gemcitabine as second line neoadjuvant therapy in locally advanced breast cancer patients

Ministry of Research, Shiraz University of Medical Sciences, Pharmaceutical Sciences Research Center0 sites50 target enrollmentTBD

Overview

Phase
Phase 2
Intervention
Not specified
Conditions
Breast cancer.
Sponsor
Ministry of Research, Shiraz University of Medical Sciences, Pharmaceutical Sciences Research Center
Enrollment
50
Status
Recruiting
Last Updated
8 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
8 years ago
Study Type
Interventional
Sex
Female

Investigators

Sponsor
Ministry of Research, Shiraz University of Medical Sciences, Pharmaceutical Sciences Research Center

Eligibility Criteria

Inclusion Criteria

  • Female patients; Diagnosed with locally advanced breast cancer; 18 to 60 years of age. Exclusion criteria: Evidence of metastasis; Inflammatory breast cancer; Abnormal kidney function (Serum creatinine \> 1\.5 mg/dl); Abnormal liver function (Bilirubin and Serum transaminase \> 2xULN); Abnormal Bone marrow function (Abnormal hemoglobin, WBC and platelet count)

Exclusion Criteria

  • Not provided

Outcomes

Primary Outcomes

Not specified

Similar Trials